Theresa Deisher

AVM Biotechnology's clinical research uncovered a reserve immune system that is activated by our lead small molecule, AVM0703. AVM was named a National Institute of Health 2024 Innovation Company, a National Cancer Institute 2023 Showcase Company and a NIH/NIDDK 2022 Showcase Company. AVM Biotechnology is a clinical stage biotech developing small molecule therapeutics for the treatment of cancer. Lead product, AVM0703, has demonstrated exceptional clinical efficacy and no safety concerns in a variety of solid tumors and blood cancers. AVM0703 induces and mobilizes immune cells naturally programmed to recognize all types of cancer enabling its potential as a pan-cancer therapy. First indication for approval is relapsed/refractory Non-Hodgkin’s Lymphoma. Low cost of goods translates to accessibility and annual $$ billion+ drug.